Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting

Indirect Assessment and Intervention for Perinatal Drug Use

This study has been completed.
National Institute on Drug Abuse (NIDA)
Information provided by (Responsible Party):
Steven J. Ondersma, Wayne State University Identifier:
First received: July 13, 2012
Last updated: December 7, 2015
Last verified: December 2015
The purpose of this study is to assess the validity of an indirect computer-delivered screener for drug use and assess the efficacy of a computer-delivered brief intervention with urban post-partum women at-risk for substance abuse and HIV during the post-partum period.

Condition Intervention Phase
Drug Abuse
Behavioral: WIDUS computer-delivered, indirect brief intervention
Behavioral: Nutrition time control/placebo intervention
Phase 2

Study Type: Interventional
Study Design: Allocation: Randomized
Endpoint Classification: Efficacy Study
Intervention Model: Parallel Assignment
Masking: Double Blind (Subject, Outcomes Assessor)
Primary Purpose: Screening
Official Title: Indirect Assessment and Intervention for Perinatal Drug Use

Resource links provided by NLM:

Further study details as provided by Wayne State University:

Primary Outcome Measures:
  • Number of drug using days [ Time Frame: since last research visit; up to 90 days prior to current evaluation ] [ Designated as safety issue: No ]
    Drug use over past 90 days will be measured at a 3 and 6-month follow-up by self-report, hair, and urine analysis.

  • Change from Baseline HIV and other STI risk at 3 months [ Time Frame: since last research visit; up to 90 days from baseline visit ] [ Designated as safety issue: No ]
    Self-report of risky sexual and/or injection drug use that could place participants at risk of HIV and other STIs

  • Change from Baseline in HIV and Other STI Risk at 6 months [ Time Frame: since last research visit; up to 180 days since baseline visit ] [ Designated as safety issue: No ]
    Self-report of risky sexual and/or injection drug use that could place participants at risk of HIV and other STIs

Enrollment: 500
Study Start Date: June 2012
Study Completion Date: May 2015
Primary Completion Date: November 2014 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Placebo Comparator: Control
Participants randomized into the control condition complete assessment and a time-matched interactive session on infant nutrition.
Behavioral: Nutrition time control/placebo intervention
This time-control intervention, designed in part to help promote RA blinding as to participant condition, focuses on proper infant nutrition using a computer-delivered, interactive format and videos.
Experimental: Indirect intervention
Participants in this condition review a short series of parenting strengths that benefit infants, and are invited to consider their current status in each area. This list includes factors associated with drug use (e.g., safety, emotional health) as well as substance use itself.
Behavioral: WIDUS computer-delivered, indirect brief intervention
A single 20-minute interactive computer-delivered intervention designed to promote motivation to change drug use and risky sexual behavior, if any, without presuming those risks to be specifically present.

Detailed Description:
Two factors limit the potential of brief interventions for the reduction of substance abuse and HIV risk. First, the ability to conduct such interventions is dependent upon willingness to disclose drug use and risky sexual behaviors. This is a significant obstacle given evidence that as few as half of drug-positive individuals-particularly women in the perinatal period-report that use. Second, there are logistic and financial obstacles to implementing even brief intervention programs, particularly with regard to time, training and provider willingness. In response to these limitations, and with NIDA support (DA018975), the Parent Health Lab at the Wayne State University School of Medicine developed and validated a sensitive indirect screener that evaluates correlates of illicit drug use rather than drug use itself. The Lab also developed a brief computer-delivered intervention designed to build change motivation without presuming the presence of risks to accompany the screener. This intervention demonstrated excellent feasibility and acceptability in Phase I testing. Following NIDA's Stage Model of Behavioral Therapy Development, the proposed study will take the next step of validating the computer-delivered indirect screening and intervention process in a Phase II/Stage IIb trial with women determined to be at risk by the indirect drug use screener. In addition, given that 47.8% of the prior sample's participants had an STI at some point in their lives, the proposed study will also further expand the existing focus on HIV risk. Specifically, we plan to: (a) continue development and validation of the WIDUS screener via concomitant collection of WIDUS protocols and hair/urine samples, as well as by building its ability to indirectly predict HIV risk; (b) revise and upgrade the draft indirect intervention based on expert and participant informant feedback; (c) recruit 500 at-risk women from an urban obstetric hospital; and (d) randomly assign participants into intervention and control conditions, with blinded follow-up assessments at 3- and 6-months. If proven efficacious, this logistically feasible, replicable, and low-cost approach could allow a dramatic increase in the reach--and therefore the population impact--of brief interventions for drug use among at-risk post-partum women. Further, any impact on maternal drug use would be further multiplied by indirect effects on the at-risk child.

Ages Eligible for Study:   18 Years to 45 Years   (Adult)
Genders Eligible for Study:   Female
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • 18 years of age or older
  • able to communicate in English
  • recently gave birth to healthy infant

Exclusion Criteria:

  • received narcotic pain medication in past 3 hours
  • no sleep since giving birth
  • infant deceased or in intensive care
  • psychosis or other clear cognitive impairment
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT01650675

United States, Michigan
Wayne State University
Detroit, Michigan, United States, 48202
Sponsors and Collaborators
Wayne State University
National Institute on Drug Abuse (NIDA)
Principal Investigator: Steven J Ondersma, Ph.D. Wayne State University
  More Information

Responsible Party: Steven J. Ondersma, Associate Professor, Wayne State University Identifier: NCT01650675     History of Changes
Other Study ID Numbers: R01DA029050 
Study First Received: July 13, 2012
Last Updated: December 7, 2015
Health Authority: United States: Federal Government
United States: Institutional Review Board

Keywords provided by Wayne State University:

Additional relevant MeSH terms:
Substance-Related Disorders
Chemically-Induced Disorders
Mental Disorders processed this record on October 21, 2016